Range of suitable sufferers: CDEC talked about the uncertainty in the amount of patients with reasonably critical to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical industry experts consulted by CADTH indicated that some people that are classified as having delicate or moderate disease can have a significant https://hemgenix27260.blogdeazar.com/36228741/everything-about-hemgenix